首页> 外文期刊>Biochemical and Biophysical Research Communications >FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27
【24h】

FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27

机译:通过靶向P27,FOXD1促进乳腺癌增殖和化学治疗性药物抗性

获取原文
获取原文并翻译 | 示例

摘要

Forkhead transcription factors are essential for diverse processes in early embryonic development and organogenesis. As a member of the forkhead family, FOXD1 is required during kidney development and its inactivation results in failure of nephron progenitor cells. However, the role of FOXD1 in carcinogenesis and progression is still limited. Here, we reported that FOXD1 is a potential oncogene in breast cancer. We found that FOXD1 is up-regulated in breast cancer tissues. Depletion of FOXD1 expression decreases the ability of cell proliferation and chemoresistance in MDA-MB-231 cells, whereas overexpression of FOXD1 increases the ability of cell proliferation and chemoresistance in MCF-7 cells. Furthermore, we observed that FOXD1 induces G1 to S phase transition by targeting p27 expression. Our results suggest that FOXD1 may be a potential therapy target for patients with breast cancer. (C) 2014 Elsevier Inc. All rights reserved.
机译:Forkhead转录因子对于早期胚胎发育和器官发生的多种过程至关重要。 作为叉头家族的成员,肾脏发育期间需要FOXD1,其失活导致肾祖细胞失效。 然而,Foxd1在致癌和进展中的作用仍然有限。 在这里,我们报道了Foxd1是乳腺癌中的潜在癌症。 我们发现Foxd1在乳腺癌组织中上调。 FoxD1表达的耗竭降低了MDA-MB-231细胞中细胞增殖和化学抑制能力的能力,而FoxD1的过度表达增加了MCF-7细胞中细胞增殖和化学能力的能力。 此外,我们观察到Foxd1通过靶向P27表达来诱导G1至S相转变。 我们的研究结果表明Foxd1可能是乳腺癌患者的潜在治疗目标。 (c)2014年elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号